Time course and attenuation of ischaemia-reperfusion induced oxidative injury by propofol in human renal transplantation

Redox Report

Volumn 12, Issue 4, 2007, Pages 195-202

  Basu, Samar ^a   Meisert, Isabelle ^b   Eggensperger, Elisabeth ^b   Krieger, Elisabeth ^b   Krenn, Claus G ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Inflammation; Ischaemia reperfusion; Isoprostanes; Oxidative stress; Propofol; Prostaglandins; Renal transplantation

Indexed keywords

13,14 DIHYDRO 15 OXOPROSTAGLANDIN F2 ALPHA; 8 ISOPROSTAGLANDIN F2 ALPHA; ANESTHETIC AGENT; CISATRACURIUM; CORTISONE; CYCLOSPORIN A; DEXAMETHASONE; FENTANYL; ISOPROSTANE DERIVATIVE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OXYGEN; PROPOFOL; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN SYNTHASE; SEVOFLURANE; THIOPENTAL; ANTIOXIDANT; INTRAVENOUS ANESTHETIC AGENT; PROSTAGLANDIN F;

ADULT; ANESTHESIA INDUCTION; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INFLAMMATION; ISCHEMIA; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MALE; METABOLITE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; RADIOIMMUNOASSAY; REPERFUSION INJURY; SURGICAL TECHNIQUE; AGED; BIOLOGICAL MODEL; BLOOD; CHEMICAL STRUCTURE; CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; METABOLISM; MIDDLE AGED; OXIDATION REDUCTION REACTION; POSTOPERATIVE COMPLICATION; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME;

AGED; ANESTHETICS, INTRAVENOUS; ANTIOXIDANTS; F2-ISOPROSTANES; FEMALE; HUMANS; INFLAMMATION; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; OXIDATIVE STRESS; POSTOPERATIVE COMPLICATIONS; PROPOFOL; PROSTAGLANDINS F; REPERFUSION INJURY; THIOPENTAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 35548973469     PISSN: 13510002     EISSN: None     Source Type: Journal    
DOI: 10.1179/135100007X200281     Document Type: Article

References (38)

1. Rodeck G, Lange H. Indications and contraindications for kidney transplantation. Urologe 1982; 21: 244-248.
2. Kissmeyer-Nielsen F, Olsen S, Petersen VP, Fjeldborg O. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet 1966; 2: 662-665
3. Paul LC. Chronic allograft nephropathy: An update. Kidney Int 1999; 56:783-793.
4. Paller MS. Free radical-mediated postischemic injury in renal transplantation. Ren Fail 1992; 14: 257-260.
5. Paller MS, Greene EL. Role of calcium in reperfusion injury of the kidney. Ann NY Acad Sci 1994; 723: 59-70.
6. Webster NR, Nunn JF. Molecular structure of free radicals and their importance in biological reactions. Br J Anaesth 1988; 60: 98-108.
7. Vural A, Yilmaz MI, Caglar K et al. Assessment of oxidative stress in the early posftmsplant period: Comparison of cyclosporine A and tacrolimus-based regimens. Am J Nephrol 2005; 25:250-255
8. Basu S. Oxidative injury induced cyclooxygenase activation in experimental hepatotoxicity. Biochem Biophys Res Commun 1999; 254:764-767.
9. 4 poisoning? Free Radic Biol Med 2005; 38:698-710.
10. 2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 1990; 87: 9383-9387
11. 4, poisoning. Free Radic Biol Med 2005; 38: 711-718.
12. Morrow JD, Roberts 2nd LJ. The isoprostanes. Current knowledge and directions for future research. Biochem Pharmacol 1996; 51: 1-9.
13. Basu S. Isoprostanes: Novel bioactive compounds of lipid peroxidation. Free Radic Res 2004; 38: 105-422.
14. Morrow JD. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thrombos Vasc Biol 2005; 25: 275-286.
15. Helmersson J, Vessby B, Larsson A, Basu S. Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress inan elderly population. Circulation 2004; 109: 1729-1734.
16. Basu S, Eriksson M. Oxidative injury and survival during endotoxemia. FEBS Lett 1998; 438: 159-160.
17. Basu S, Nozari A, Liu XL, Rubertsson S, Wiklund L. Development of a novel biomarker of free radical damage in reperfusion injury after cardiac arrest. FEBS Lett 2000; 470: 1-6.
18. Basu S, Whiteman M, Mattey DL, Halliwell B. Raised levels of F(2)-isoprostanes and prostaglandin F(2alpha) in different rheumatic diseases. Ann Rheum Dis 2001; 60: 627-631.
19. Ulus AT, Aksovek A, Ozkan M, Katircioglu SF, Basu S. Cardiopulmonary bypass as a cause of free radical induced-oxidative stress and enhanced circulatory isoprostanes in humans. Free Radic Biol Med 2003; 34: 911-917.
20. Samuelsson B, Goldyne M, Granström E, Hamberg M, Hammarström S, Malmsten C. Prostaglandins and thromboxanes. Anna Rev Biochem 1978; 47: 997-929.
21. 2α from physiology to new principles in inflammation. Med Res Rev 2006; 27: 435-468.
22. Kosieradzki M, Kuczynska J, Piwowarska J. Prognostic significance of free radicals: Mediated injury occurring in the kidney donor. Transplantation 2003; 75: 1221-1227.
23. Richer JP, Gibelin H, Planet M. Ischemia-reperfusion injury is associated with inflammatory cell infiltration: Evaluation in a pig kidney autotransplant model. Transplant Proc 2000; 32: 482-483.
24. Cerwenka H, Bacher H, Werkgartner G. Antioxidant treatment during liver resection for alleviation of ischemia-reperfusion injury. Hepatogastroenterology 1998; 45: 777-782.
25. Rabl H, Khoschsorur G, Cotombo T. A multivitamin infusion prevents lipid peroxidation and improves transplantation performance. Kidney Int 1993; 43: 912-917.
26. Muratore A, Ribero D, Ferrero A, Bergero R, Capussotti L. Prospective randomized study of steroids in the prevention of ischaemic injury during hepatic resection with pedicle clamping. Br J Surg 2003; 90: 17-22.
27. Basu S, Mutschler DK, Larsson A, Kiiski R, Norgren A, Eriksson M. Propofol (Diprivan-EDTA) counteracts oxidative injury and deterioration of the arterial oxygen tension during experimental septic shock. Resuscitation 2001; 50: 341-348.
28. Basu S. Radioimmunoassay of 8-iso-prostaglandin F2alpha: An index for oxidative injury via free radical catalysed lipid peroxidation. Prostaglandin Leukoc Essent Fatty Acids 1998; 58: 319-325.
29. Basu S. Radioimmunoassay of 15-keto-13,14-dihydro-prostaglandin F2alpha: an index for inflammation via cyclooxygenase catalysed lipid peroxidation. Prostaglandin Leukoc Essent Fatty Acids 1998; 58: 347-352.
30. Buja LM. Myocardial ischemia and reperfusion injury. Cardiovasc Pathol 2005; 14: 170-175.
31. Halliwell B, Gutteridge JCM. Free Radicals in Biology and Medicine. Oxford: Oxford University Press, 1999.
32. Murphy PG, Myers DS, Davies MJ, Webster NR, Jones JG. The antioxidant potential of propofol (2,6-diisopropylphenol). Br J Anaesth 1992; 68: 613-618.
33. De La Cruz JP, Sedeno G, Carmona A, Sanchez de la Cuesta F. The in vitro effects of propofol on tissular oxidative stress in the rat. Anesth Analg 1998; 87: 1141-1146.
34. Aldemir O, Celebi H, Cevik C, Duzgun E. The effects of propofol or halothane on free radical production after tourniquet induced ischaemia-reperfusion injury during knee arthroplasty. Acta Anaesthesiol Scand 2001; 45: 1221-1225.
35. Kelicen P. Ismailoglu UB, Erdemli O, Sahin-Erdemli I. The effect of propofol and thiopentone on impairment by reactive oxygen species of endothelium-dependent relaxation in rat aortic rings. Eur J Anaesthesiol 1997; 14: 310-315.
36. Kaptanoglu E. Sen S, Beskonakli E et al. Antioxidant actions and early ultrastructural findings of thiopental and propofol in experimental spinal cord injury. J Neurosurg Anesthesiol 2002; 14:114-122.
37. De La Cruz JP, Zanca A, Carmona JA, de la Cuesta FS. The effect of propofol on oxidative stress in platelets from surgical patients. Anesth Analg 1999; 89: 1050-1055.
38. Kirvela M, Olkkola KT, Rosenberg PH, Yli-Hankala A, Salmela K, Lindgren L. Pharmacokinetics of propofol and haemodynamic changes during induction of anaesthesia in uraemic patients. Br J Anaesth 1992; 69: 178-182.